ATNX News and Press, Athenex Inc. From 03/01/21

Receipt of Complete Response Letter from the FDA for Oral Paclitaxel Plus Encequidar Klisyri® (tirbanibulin) received FDA approval and launched commercially on February 18, 2021 The New England Journal of Medicine published Phase III trial data on the efficacy and safety of K...

Conference call and webcast scheduled for today at 8:00 a.m. ET BUFFALO, N.Y., March 01, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment...

ATNX won one approval in December and has a PDUFA on Feb 28. Data says it's likely going to be approved as the first oral paclitaxel for metastatic breast cancer. ATNX is pretty undercovered, and looks like a long-term stock. For further details see: Athenex: PDUFA This ...

BUFFALO, N.Y., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will prov...

Athenex (ATNX) launches Klisyri (tirbanibulin) in the U.S., led by its partner Almirall. FDA approved Klisyri for the topical treatment of actinic keratosis of the face or scalp on December 14, 2020.Under the terms of the license agreement with Almirall, Athenex will receive up to $...

Almirall U.S. Launches Klisyri® (tirbanibulin), a New, Innovative Topical Treatment for Actinic Keratosis - Actinic keratosis (AK), the second most common diagnosis made by dermatologists in the United States(1), affects more than 40 million Americans each year(2) - Kli...

Athenex Announces Licensing of Additional Territories for the Development and Commercialization of Tirbanibulin in Japan and South Korea. PharmaEssentia Expands Tirbanibulin Partnership by Adding Japan and South Korea to Already Licensed Territories of Taiwan, Singapore, and M...

Almirall announces New England Journal of Medicine publication of Phase III data demonstrating efficacy and safety of Klisyri® (tirbanibulin) -- Klisyri® (tirbanibulin) is a novel microtubule inhibitor, recently approved by the U.S. Food and Drug Administration (FDA) f...

The New England Journal of Medicine published the Phase III trial results on Klisyri®, an anti-proliferative agent that inhibits tubulin polymerization and Src kinase signaling, for the topical treatment of actinic keratosis (AK) of the face or scalp Klisyri®, develo...

BUFFALO, N.Y., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that its CEO and Board...